Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2seventy bio, Inc. - Common Stock (NQ: TSVT ) 4.500 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about 2seventy bio, Inc. - Common Stock < Previous 1 2 3 4 Next > 3 Hidden Stock Gems That Wall Street Is Overlooking July 05, 2024 If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. Via InvestorPlace Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma June 27, 2024 2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... Via Benzinga TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 May 08, 2024 TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies April 19, 2024 Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel Via Benzinga Exposures Product Safety FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer April 05, 2024 FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... Via Benzinga Exposures Product Safety A Preview Of 2seventy bio's Earnings March 04, 2024 Via Benzinga 2seventy bio: Q3 Earnings Insights November 14, 2023 Via Benzinga Preview: 2seventy bio's Earnings November 13, 2023 Via Benzinga Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 18, 2024 Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. Via Benzinga FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer March 18, 2024 FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session March 18, 2024 Via Benzinga Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket March 18, 2024 Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday March 18, 2024 Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday! Via InvestorPlace Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket March 15, 2024 Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. Via Benzinga Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley March 07, 2024 Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. Via Benzinga TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 March 05, 2024 TSVT stock results show that 2seventy bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. Via InvestorPlace Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? February 02, 2024 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. Via Benzinga Earnings Scheduled For March 5, 2024 March 05, 2024 Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. Via Benzinga Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 31, 2024 Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session January 31, 2024 Via Benzinga Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results January 31, 2024 U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 200 points on Wednesday. The Dow traded up 0.08% to 38,497.13 while the NASDAQ fell 1.41% to... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Tuesday's Intraday Session January 30, 2024 Via Benzinga Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion January 07, 2024 Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... Via Talk Markets Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December December 19, 2023 Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... Via Benzinga Topics ETFs Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies November 29, 2023 Tuesday, the FDA said it received reports of patients developing T-cell malig Via Benzinga Exposures Product Safety Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session November 20, 2023 Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... Via Benzinga Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today? November 20, 2023 Shares of Bristol-Myers Squibb Company (NYSE: BMY) and 2seventy Bio Inc (NASDAQ: TSVT) fell after the companies' efforts to win expanded U.S. Via Benzinga 3 Biotech Stocks With Key Catalysts Coming in December November 15, 2023 Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. Via InvestorPlace 12 Health Care Stocks Moving In Thursday's Intraday Session October 26, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 October 12, 2023 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.